# Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

> **NCT01772420** · PHASE2 · COMPLETED · sponsor: **Albert Einstein College of Medicine** · enrollment: 52 (actual)

## Conditions studied

- Adult Myelodysplastic Syndrome
- Anemia
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** Eltrombopag Olamine
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01772420
- **Lead sponsor:** Albert Einstein College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2020-07-09
- **Final completion:** 2020-07-09
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2023-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01772420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01772420, "Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01772420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*